- Home
- ABLV vs LTRN Comparison
ABLV vs LTRN Comparison
Compare ABLV & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | LTRN |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 27.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABLV | LTRN |
|---|---|---|
| Price | $1.12 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 211.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.11 |
| 52 Week High | $1.30 | $4.70 |
Technical Indicators
Market Signals| Indicator | ABLV | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 21.47 |
| Support Level | $0.61 | $1.11 |
| Resistance Level | $1.20 | $1.96 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 100.00 | 4.71 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.